Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants

Abstract

Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin cancer treatments. Nevertheless, these innate immune system-activating drugs have potentially much broader therapeutic utility; they have been pursued as antitumor immunomodulatory agents and more recently as candidate vaccine adjuvants for cancer and infectious disease. The broad expression profiles of TLR7/8, poor pharmacokinetic properties of IMDs, and toxicities associated with systemic administration, however, are formidable barriers to successful clinical translation. Herein, we review IMD formulations that have advanced to the clinic and discuss issues related to biodistribution and toxicity that have hampered the further development of these compounds. Recent strategies aimed at enhancing safety and efficacy, particularly through the use of bioconjugates and nanoparticle formulations that alter pharmacokinetics, biodistribution, and cellular targeting, are described. Finally, key aspects of the biology of TLR7 signaling, such as TLR7 tolerance, that may need to be considered in the development of new IMD therapeutics are discussed.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 360

1. 1.

   Miller RL, Gerster JF, Owens ML, Slade HB, a Tomai M, Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug, Int J Immunopharmaco. 21 (1999 ) 1–14..

   Not in our library10.1016/s0192-0561(98)00068-x

2. 2.

   O’Neill LAJ, Golenbock D, Bowie AG, The history of Toll-like receptors — redefining innate immunity, Nat Rev Immunol. 13 (2013 ) 453–460..

   Not in our library10.1038/nri3446

3. 3.

   Gerster JF, 1H-imidazo[4,5-c]quinolin-4-amines and antiviral use, 4,689,338, 1987. https://patentimages.storage.googleapis.com/f3/d6/dd/f2177153a97ae4/US4689338.pdf.

   Not in our library

4. 4.

   Ryu J, Yang FC, A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions, Clin Medicine Ther. 1 (2009 ) CMT.S1969..

   Not in our library10.4137/cmt.s1969

5. 5.

   Tomai MA, Gibson SJ, Imbertson LM, Miller RL, Myhre PE, Reiter MJ, Wagner TL, Tamulinas CB, Beaurline JM, Gerster JF, Horton VL, Immunomodulating and antiviral activities of the imidazoquinoline S-28463, Antivir Res. 28 (1995 ) 253–264..

   Not in our library10.1016/0166-3542(95)00054-p

6. 6.

   Hirota K, Kazaoka K, Niimoto I, Kumihara H, Sajiki H, Isobe Y, Takaku H, Tobe M, Ogita H, Ogino T, Ichii S, Kurimoto A, Kawakami H, Discovery of 8-hydroxyadenines as a novel type of interferon inducer., Journal of Medicinal Chemistry. 45 (2002 ) 5419–22..

   Not in our library10.1021/jm0203581

7. 7.

   Dockrell DH, Kinghorn GR, Imiquimod and resiquimod as novel immunomodulators, J Antimicrob Chemoth. 48 (2001 ) 751–755..

   Not in our library10.1093/jac/48.6.751

8. 8.

   Wu J, Huang D, Tyring S, Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses, Antivir Res. 64 (2004 ) 79–83..

   Not in our library10.1016/j.antiviral.2004.07.002

9. 9.

   Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng T, A phase II dose-ranging study of topical resiquimod to treat actinic keratosis, Brit J Dermatol. 159 (2008 ) 205–210..

   Not in our library10.1111/j.1365-2133.2008.08615.x

10. 10.

    Tarabadkar ES, Shinohara MM, Skin Directed Therapy in Cutaneous T-Cell Lymphoma, Frontiers Oncol. 9 (2019 ) 260..

    Not in our library10.3389/fonc.2019.00260

11. 11.

    Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S, Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway, Nature Immunology. 3 (2002 )..

    Not in our library10.1038/ni758

12. 12.

    Kawai T, Akira S, TLR signaling, Semin Immunol. 19 (2007 ) 24–32..

    Not in our library10.1016/j.smim.2006.12.004

13. 13.

    Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP, TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN., J Interf Cytokine Res Official J Int Soc Interf Cytokine Res. 28 (2008 ) 253–63..

    Not in our library10.1089/jir.2007.0097

14. 14.

    Cheever MA, Twelve immunotherapy drugs that could cure cancers., Immunol Rev. 222 (2008 ) 357–68..

    Not in our library10.1111/j.1600-065x.2008.00604.x

15. 15.

    Engel AL, Holt GE, Lu H, The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system, Expert Rev Clin Phar. 4 (2014 ) 275–289..

    Not in our library10.1586/ecp.11.5

16. 16.

    Dong Z, Xiong L, Zhang W, Gibson PG, Wang T, Lu Y, Wang G, Li H, Wang F, Holding the Inflammatory System in Check: TLRs and Their Targeted Therapy in Asthma, Mediat Inflamm. 2016 (2016 ) 1–8..

    Not in our library10.1155/2016/2180417

17. 17.
    Recent clinical trends in Toll‐like receptor targeting therapeutics · 2018

    No notice
18. 18.

    Medzhitov R, Toll-like receptors and innate immunity, Nat Rev Immunol. 1 (2001 ) 135–145..

    Not in our library10.1038/35100529

19. 19.

    Shimizu T, Structural insights into ligand recognition and regulation of nucleic acid-sensing Toll-like receptors, Curr Opin Struc Biol. 47 (2017 ) 52–59..

    Not in our library10.1016/j.sbi.2017.05.010

20. 20.

    Groß CJ, Mishra R, Schneider KS, Médard G, Wettmarshausen J, Dittlein DC, Shi H, Gorka O, Koenig P-A, Fromm S, Magnani G, Ćiković T, Hartjes L, Smollich J, Robertson AAB, Cooper MA, Schmidt-Supprian M, Schuster M, Schroder K, Broz P, Traidl-Hoffmann C, Beutler B, Kuster B, Ruland J, Schneider S, Perocchi F, Groß O, K + Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria, Immunity. 45 (2016 ) 761–773..

    Not in our library10.1016/j.immuni.2016.08.010

21. 21.

    Milling L, Zhang Y, Irvine DJ, Delivering safer immunotherapies for cancer, Adv Drug Deliver Rev. 114 (2017 ) 79–101..

    Not in our library10.1016/j.addr.2017.05.011

22. 22.

    Takeda K, Kaisho T, Akira S, Toll-like receptors., Annual Review of Immunology. 21 (2003 ) 335–76..

    Not in our library10.1146/annurev.immunol.21.120601.141126

23. 23.

    Diebold SS, Kaisho T, Hemmi H, Akira S, e Sousa CR, Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA, Science. 303 (2004 ) 1529–1531..

    Not in our library10.1126/science.1093616

24. 24.

    Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S, Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8, Science. 303 (2004 ) 1526–1529..

    Not in our library10.1126/science.1093620

25. 25.

    Takeuchi O, Akira S, Pattern Recognition Receptors and Inflammation, Cell. 140 (2010 ) 805–820..

    Not in our library10.1016/j.cell.2010.01.022

26. 26.

    Leulier F, Lemaitre B, Toll-like receptors — taking an evolutionary approach, Nat Rev Genet. 9 (2008 ) 165–178..

    Not in our library10.1038/nrg2303

27. 27.

    Akira S, Takeda K, Kaisho T, Toll-like receptors: critical proteins linking innate and acquired immunity, Nature Immunology. 2 (2001 )..

    Not in our library10.1038/90609

28. 28.

    Janssens S, Beyaert R, A universal role for MyD88 in TLR/IL-1R-mediated signaling, Trends Biochem Sci. 27 (2002 ) 474–482..

    Not in our library10.1016/s0968-0004(02)02145-x

29. 29.

    Kawagoe T, Sato S, Jung A, Yamamoto M, Matsui K, Kato H, Uematsu S, Takeuchi O, Akira S, Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor–mediated immune responses but not in TCR signaling, J Exp Medicine. 204 (2007 ) 1013–1024..

    Not in our library10.1084/jem.20061523

30. 30.

    Kawai T, Akira S, TLR signaling, Cell Death Differ. 13 (2006 ) 816–825..

    Not in our library10.1038/sj.cdd.4401850

31. 31.

    Gay NJ, Symmons MF, Gangloff M, Bryant CE, Assembly and localization of Toll-like receptor signalling complexes, Nat Rev Immunol. 14 (2014 ) 546–558..

    Not in our library10.1038/nri3713

32. 32.

    Kawai T, Akira S, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nat Immunol. 11 (2010 ) 373–84..

    Not in our library10.1038/ni.1863

33. 33.

    Bell E, Intracellular trafficking, IRF7 and type-I-IFN responses, Nat Rev Immunol. 5 (2005 ) 361–361..

    Not in our library10.1038/nri1625

34. 34.

    Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, Endres S, Hartmann G, Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides, J Immunol. 168 (2002 ) 4531–4537..

    Not in our library10.4049/jimmunol.168.9.4531

35. 35.

    Iwasaki A, Medzhitov R, Toll-like receptor control of the adaptive immune responses, Nat Immunol. 5 (2004 ) 987–995..

    Not in our library10.1038/ni1112

36. 36.

    e Sousa CR, Toll-like receptors and dendritic cells: for whom the bug tolls., Seminars in Immunology. 16 (2004 ) 27–34..

    Not in our library10.1016/j.smim.2003.10.004

37. 37.

    Iwasaki A, Medzhitov R, Control of adaptive immunity by the innate immune system, Nat Immunol. 16 (2015 ) 343–353..

    Not in our library10.1038/ni.3123

38. 38.

    Trinchieri G, Sher A, Cooperation of Toll-like receptor signals in innate immune defence, Nat Rev Immunol. 7 (2007 ) 179–190..

    Not in our library10.1038/nri2038

39. 39.
    The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome · 2017

    No notice
40. 40.

    Merad M, Sathe P, Helft J, Miller J, Mortha A, The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting., Annu Rev Immunol. 31 (2013 ) 563–604..

    Not in our library10.1146/annurev-immunol-020711-074950

Cited by papers we hold 3

• Vaccine adjuvants: mechanisms and platforms · 2023
  No notice
• Type I interferon-mediated tumor immunity and its role in immunotherapy · 2022
  No notice
• An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.